Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083697 | 1.00 | ACE (0.46) | ACEALDH1A1SMN1; SMN2ATMPHGDH | |
| SCHEMBL14655396 | 0.84 | ACE (0.47) | ACEALDH1A1ATMPHGDHKMT2A | |
| SCHEMBL16635521 | 0.84 | ACE (0.47) | ACEALDH1A1ATMPHGDHKMT2A | |
| SCHEMBL6039468 | 0.84 | ACE (0.47) | ACEALDH1A1ATMPHGDHKMT2A | |
| SCHEMBL15389898 | 0.84 | ACE (0.47) | ACEALDH1A1ATMPHGDHKMT2A | |
| SCHEMBL20399837 | 0.84 | ACE (0.47) | ACEALDH1A1ATMPHGDHKMT2A | |
| SCHEMBL3832250 | 0.84 | ACE (0.47) | ACEALDH1A1ATMPHGDHKMT2A | |
| SCHEMBL8271433 | 0.84 | SMN1; SMN2 (0.40) | ACEALDH1A1SMN1; SMN2PHGDHRECQL | |
| SCHEMBL16317261 | 0.84 | SMN1; SMN2 (0.40) | ACEALDH1A1SMN1; SMN2PHGDHRECQL | |
| SCHEMBL16300651 | 0.84 | SMN1; SMN2 (0.40) | ACEALDH1A1SMN1; SMN2PHGDHRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ACE 1083/4885ALDH1A1 1155/4885SMN1; SMN2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.